《大行》瑞銀升中國太保(02601.HK)目標價至37元 料次季稅後淨利潤反彈
瑞銀髮表研究報告指,預計中國太保(02601.HK)上半年除稅後淨利潤按年增長8%,意味着第二季按年躍升31%,相信是由於股票市場表現改善及利率急速下降導致債券價值增加。就稅後經營利潤而言,預估上半年按年增長6%,相較於首季可能略爲加快。淨資產值方面,該行估計上半年較去年年底降3.2%,按季則升7%。根據該公司對今年稅後經營利潤的指引,該行估計股息按年增3%至1.11元人民幣。
該行認爲,包括中國太保在內的國企保險公司,很有可能在市場動盪的情況下提出回購,以顯示穩定資本市場的承諾。該行上調中國太保今明兩年的除稅後淨利潤預測11%和4%,目標價由33元升至37元,維持「買入」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.